As biotechnology firms evolve from research-focused organizations into commercial powerhouses, their equity compensation strategies must undergo a strategic shift. This session will explore the “why” and “how” of updating pre-commercial frameworks, equity vehicles, and performance metrics to align with the demands of a commercial environment. Participants will examine the challenges of balancing stakeholder expectations, maintaining executive focus, and designing equity programs that drive long-term commercial success.

KEY LEARNINGS:

• How to evolve equity compensation frameworks as biotech firms transition from research to commercial operations.
• Strategies for aligning equity vehicles and performance metrics with stakeholder priorities and commercial goals.
• Practical insights for maintaining executive focus while supporting the firm’s path to sustainable growth.